Why is SCHOTT Pharma stock rallying today?
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SCHOTT Pharma AG & Co KgaA (1SXP)
The SCHOTT Pharma share price today is 22.75, view ETR 1SXP stock exchange data. Track the latest SCHOTT Pharma share price with real-time updates on 1SXP stock performance including market cap, day range, 52-week range and dividend yield. Access 1SXP charts, earnings dates and analyst estimates to support your investment decisions.
Currency in EUR
22.75
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.65
23.05
52 wk Range
12.62
24.00
1SXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.6523.05
52 wk Range
12.6224.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.79%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.79%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1SXP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
22.61
Downside
-0.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
SCHOTT Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Why is SCHOTT Pharma stock rallying today?
- Investing.com
- SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
SCHOTT Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
9 Buy
2 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 22.61
(-0.62% Downside)
SCHOTT Pharma AG & Co KgaA Earnings Call Summary for Q3/2026
- Q3 revenue hit EUR 282M, beating forecast by EUR 10M; full-year growth guidance raised to 5%-6% from 2%-5% on broad-based demand improvement.
- EBITDA margin fell to 26.8% from 32.3% year-over-year; full-year margin guidance lifted to 27%-28% with Q4 step-up expected despite profitability pressure.
- High-value solutions reached 59% of Q3 revenue, nearing 60% midterm target; free cash flow surged 49% year-over-year to EUR 58.9M for nine months.
- EUR 15M one-time glass syringe contract benefit to support 2026 growth but create 2027 headwind; capex expected at EUR 140-160M in 2026, rising in 2027.
- Stock declined 1.12% to $22.15 despite beat; shares up 49% year-to-date but remain 8.1% below 52-week high amid margin concerns and elevated expectations.
Last Updated: 12-08-2026, 03:24 pm
Read Full TranscriptEarnings
Latest Release
12-08-2026
EPS / Forecast
0.25 / 0.25
Revenue / Forecast
281.8M / 272.03M
Compare 1SXP to Peers and Sector
Metrics to compare | 1SXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1SXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.2x | 24.7x | −0.3x | |
PEG Ratio | −3.47 | −0.16 | 0.00 | |
Price/Book | 3.4x | 2.2x | 2.6x | |
Price / LTM Sales | 3.4x | 2.2x | 3.1x | |
Upside (Analyst Target) | 5.5% | 27.2% | 48.5% | |
Fair Value Upside | Unlock | 12.6% | 6.3% | Unlock |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the SCHOTT Pharma (1SXP) Share Price Today?
The SCHOTT Pharma share price today is 22.75.
What is the current SCHOTT Pharma (1SXP) share price and day range?
As of 20-08-2026, the SCHOTT Pharma share price is 22.75, with a previous close of 22.75. The share price has ranged from 22.65 to 23.05 today, while the 52-week range spans from 12.62 to 24.00.
What Is the SCHOTT Pharma Market Cap?
As of today, SCHOTT Pharma market cap is 3.43B.
Does SCHOTT Pharma Pay Dividends? What's The Current Dividend Yield?
The SCHOTT Pharma dividend yield is 0.79%.
What Is the SCHOTT Pharma (1SXP) Share Price Target?
The average 12-month share price target for SCHOTT Pharma is 22.61, with a high estimate of 27 and a low estimate of 13. 9 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and -0.62% Downside potential.
What Is SCHOTT Pharma's Earnings Per Share (TTM)?
The SCHOTT Pharma EPS (TTM) is 0.90.
When Is the Next SCHOTT Pharma Earnings Date?
SCHOTT Pharma will release its next earnings report on 10-12-2026.
From a Technical Analysis Perspective, Is 1SXP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does SCHOTT Pharma Trade On?
SCHOTT Pharma is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for SCHOTT Pharma?
The stock symbol for SCHOTT Pharma is "1SXP."
How Many Times Has SCHOTT Pharma Stock Split?
SCHOTT Pharma has split 0 times.
How Many Employees Does SCHOTT Pharma Have?
SCHOTT Pharma has 5002 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.